Caio Max Rocha Lima to Antimetabolites, Antineoplastic
This is a "connection" page, showing publications Caio Max Rocha Lima has written about Antimetabolites, Antineoplastic.
Connection Strength
1.213
-
Burris H, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist. 2008 Mar; 13(3):289-98.
Score: 0.302
-
Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004 Sep 15; 22(18):3776-83.
Score: 0.237
-
Shoemaker LK, Arora U, Rocha Lima CM. 5-fluorouracil-induced coronary vasospasm. Cancer Control. 2004 Jan-Feb; 11(1):46-9.
Score: 0.226
-
Rocha Lima CM, Eckardt JR, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, Bahadori HR, Green MR. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer. Semin Oncol. 1999 Oct; 26(5 Suppl 16):43-50; discussion 71-2.
Score: 0.168
-
Bayraktar S, Bayraktar UD, Rocha-Lima CM. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol. 2010 Feb 14; 16(6):673-82.
Score: 0.086
-
Vulfovich M, Rocha-Lima C. Novel advances in pancreatic cancer treatment. Expert Rev Anticancer Ther. 2008 Jun; 8(6):993-1002.
Score: 0.077
-
Khanna A, Walker GR, Livingstone AS, Arheart KL, Rocha-Lima C, Koniaris LG. Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg. 2006 May; 10(5):689-97.
Score: 0.066
-
Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002 Mar 01; 20(5):1182-91.
Score: 0.050